OSCR
Oscar Health, Inc.
OSCR has the edge over UTMD overall, supported by stronger fundamentals and stronger modeled upside.
UTMD
Utah Medical Products, Inc.
UTMD has slightly lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
UTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Healthy | |
| Strong |
UTMD's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over UTMD in the historical PE scenario, which offers more potential upside but is not a forecast.
UTMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $50.18 | -32% |
| Fair | 20x | $66.55 | -9.6% |
| Current | 22x | $73.63 | — |
| Expensive | 26x | $84.11 | +14% |
Historical ranges are pointers, not guarantees.
UTMD's PE is in its expensive range at 22x.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
UTMD Forward outlook
There aren't enough analyst estimates for UTMD to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over UTMD on earnings, with more consistent year-over-year improvement.
UTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.28 | -12% |
| Q1 2026 | $3.38 | -11% |
| Q4 2025 | $3.48 | -12% |
| Q3 2025 | $3.54 | -17% |
| Q2 2025 | $3.74 | -14% |
| Q1 2025 | $3.78 | -16% |
| Q4 2024 | $3.95 | -14% |
| Q3 2024 | $4.27 | -8% |
UTMD's earnings per share have fallen from their peak: $3.28 over the past year, against $4.74 in mid-2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over UTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
UTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.5M | -14% |
| Q1 2026 | $8.7M | -10% |
| Q4 2025 | $9M | -1.2% |
| Q3 2025 | $9.8M | -1.9% |
| Q2 2025 | $10M | -4.3% |
| Q1 2025 | $9.7M | -14% |
| Q4 2024 | $9.2M | -26% |
| Q3 2024 | $10M | -20% |
UTMD's revenue has slid since its 2022 peak: $9M last quarter, down 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | -1.1 points |
| Q1 2026 | 29% | -3.1 points |
| Q4 2025 | 27% | -5 points |
| Q3 2025 | 27% | -6.8 points |
| Q2 2025 | 32% | -1 points |
| Q1 2025 | 32% | -1.8 points |
| Q4 2024 | 32% | 0 points |
| Q3 2024 | 33% | +1.7 points |
UTMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over UTMD on cash flow, with more consistent year-over-year improvement.
UTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $1.2M | -56% |
| Q1 2026 | $3M | -30% |
| Q4 2025 | $3.4M | +15% |
| Q3 2025 | $3.9M | +2.2% |
| Q2 2025 | $2.8M | +6.4% |
| Q1 2025 | $4.3M | -19% |
| Q4 2024 | $2.9M | -44% |
| Q3 2024 | $3.8M | -24% |
UTMD's free cash flow has been positive every quarter for seven years: $11M over the past year, down 17% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
UTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1K shares |
| 1 year | -1.9% | -62K shares |
| 3 years | -13% | -455K shares |
| 5 years | -13% | -471K shares |
| Available history | -15% | -553K shares |
UTMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $78,000 |
| Q1 2026 | $128,000 |
| Q4 2025 | $994,000 |
| Q3 2025 | $653,000 |
| Q2 2025 | $3.5M |
| Q1 2025 | $3.2M |
| Q4 2024 | $6.7M |
| Q3 2024 | $3.9M |
UTMD spent $2M buying back its own shares over the past year, down 89% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
UTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -6.9x | Net Cash |
| Q1 2026 | -6.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -5.7x | Net Cash |
| Q2 2025 | -5.3x | Net Cash |
| Q1 2025 | -5.3x | Net Cash |
| Q4 2024 | -5.1x | Net Cash |
| Q3 2024 | -5.0x | Net Cash |
UTMD has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
UTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.3 | Neutral |
| Stochastic | 45.8 | Neutral |
UTMD's weekly RSI is 56 (neutral) and its Stochastic is 46 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over UTMD on valuation relative to its sector.
UTMD PE vs Healthcare Sector
| Metric | UTMD | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 26x | 13% below |
| PE % | 68 | 29 | 39 pts above |
UTMD is trading at 22x earnings, a 13% discount to the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
UTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $73.2 | 0.6% above |
| 20 week MA | $71.7 | 2.6% above |
| 50 week MA | $66.9 | 10% above |
| 100 week MA | $62.5 | 18% above |
| 200 week MA | $71.0 | 3.7% above |
UTMD has climbed back above all five of its weekly moving averages, and it's now 3.7% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over UTMD on returns for 2026, with the stronger performance.
UTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.4 | $85.5 | -21% |
| 2021 | $85.5 | $97.9 | +15% |
| 2022 | $97.9 | $93.6 | -4.4% |
| 2023 | $93.6 | $84.2 | -10% |
| 2024 | $84.2 | $61.9 | -27% |
| 2025 | $61.9 | $56.8 | -8.3% |
| 2026 YTD | $56.8 | $73.6 | +30% |
UTMD has finished four years in a row lower, and it's up 30% so far in 2026.